Literature DB >> 2974046

Binding of Lys-plasminogen to monocytes/macrophages.

R L Silverstein1, R J Friedlander, R L Nicholas, R L Nachman.   

Abstract

The ability of mononuclear phagocytes to assemble and activate components of the fibrinolytic system on their surfaces may be crucial in effecting an efficient inflammatory response. Lys-plasminogen, the plasmin modified form of this zymogen, was found to bind specifically and with high affinity to murine peritoneal macrophages and to cells of the human monocytoid line U937. This modified plasminogen has been shown to be a more efficient substrate for plasminogen activators than native Glu-plasminogen. Binding was lysine binding site dependent, rapid and reversible. In contrast, although native Glu-plasminogen bound specifically to these cells, affinity was low. Lys-plasminogen inhibited the binding of Glu-plasminogen but the opposite was not true. Molecular analysis of the bound ligands indicated that Glu-plasminogen was converted to Lys-plasminogen and Lys-plasminogen to plasmin on the cell surface but not in the supernatant. Peritoneal macrophages from patients with indwelling catheters and tissue macrophages in chronic inflammatory lesions were shown to express immunologically identified Lys-plasminogen on their surfaces. Therefore binding and surface activation of kinetically favored Lys-plasminogen may provide an important physiological mechanism for localizing proteolytic activity on the surface of inflammatory cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2974046      PMCID: PMC442776          DOI: 10.1172/JCI113814

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  27 in total

1.  Monoclonal antibodies against plasminogen and alpha-2-antiplasmin: binding to native and modified antigens.

Authors:  E Hattey; J Wojta; B R Binder
Journal:  Thromb Res       Date:  1987-03-01       Impact factor: 3.944

2.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

3.  Characterization of human plasminogen. II. Separation and partial characterization of different molecular forms of human plasminogen.

Authors:  P Wallén; B Wiman
Journal:  Biochim Biophys Acta       Date:  1972-01-26

4.  Comparison of some properties of native (Glu) and modified (Lys) human plasminogen.

Authors:  G Markus; J L Evers; G H Hobika
Journal:  J Biol Chem       Date:  1978-02-10       Impact factor: 5.157

5.  Establishment and characterization of a human histiocytic lymphoma cell line (U-937).

Authors:  C Sundström; K Nilsson
Journal:  Int J Cancer       Date:  1976-05-15       Impact factor: 7.396

6.  Plasminogen activator in early embryogenesis: enzyme production by trophoblast and parietal endoderm.

Authors:  S Strickland; E Reich; M I Sherman
Journal:  Cell       Date:  1976-10       Impact factor: 41.582

7.  Quantitative determination of the binding of epsilon-aminocaproic acid to native plasminogen.

Authors:  G Markus; J L DePasquale; F C Wissler
Journal:  J Biol Chem       Date:  1978-02-10       Impact factor: 5.157

8.  Activation of human plasminogen by an insoluble derivative of urokinase. Structural changes of plasminogen in the course of activation to plasmin and demonstration of a possible intermediate compound.

Authors:  B Wiman; P Wallén
Journal:  Eur J Biochem       Date:  1973-07-02

9.  Secretion of plasminogen activator by normal, reactive and neoplastic human tissues cultured in vitro.

Authors:  E L Wilson; E Dowdle
Journal:  Int J Cancer       Date:  1978-10-15       Impact factor: 7.396

10.  Secretion of plasminogen activator by stimulated macrophages.

Authors:  J C Unkeless; S Gordon; E Reich
Journal:  J Exp Med       Date:  1974-04-01       Impact factor: 14.307

View more
  10 in total

Review 1.  The annexin A2 system and vascular homeostasis.

Authors:  Elle C Flood; Katherine A Hajjar
Journal:  Vascul Pharmacol       Date:  2011-03-29       Impact factor: 5.773

2.  Specific conformational changes of plasminogen induced by chloride ions, 6-aminohexanoic acid and benzamidine, but not the overall openness of plasminogen regulate, production of biologically active angiostatins.

Authors:  Debra J Warejcka; Sally S Twining
Journal:  Biochem J       Date:  2005-12-15       Impact factor: 3.857

3.  Regulation of plasminogen receptor expression on human monocytes and monocytoid cell lines.

Authors:  J Felez; L A Miles; J Plescia; E F Plow
Journal:  J Cell Biol       Date:  1990-10       Impact factor: 10.539

Review 4.  New insights into the role of Plg-RKT in macrophage recruitment.

Authors:  Lindsey A Miles; Shahrzad Lighvani; Nagyung Baik; Caitlin M Parmer; Sophia Khaldoyanidi; Barbara M Mueller; Robert J Parmer
Journal:  Int Rev Cell Mol Biol       Date:  2014       Impact factor: 6.813

Review 5.  Plasminogen receptors: the first quarter century.

Authors:  Lindsey A Miles; Robert J Parmer
Journal:  Semin Thromb Hemost       Date:  2013-03-26       Impact factor: 4.180

6.  Specific inhibition of the activity of the urokinase receptor-mediated cell-surface plasminogen activation system by suramin.

Authors:  V Ellis; K Danø
Journal:  Biochem J       Date:  1993-12-01       Impact factor: 3.857

Review 7.  Fibrinolytic mechanisms in tumor growth and spreading.

Authors:  T Südhoff; W Schneider
Journal:  Clin Investig       Date:  1992-08

8.  tPA receptors and the fibrinolytic response in multiple sclerosis lesions.

Authors:  Djordje Gveric; Blanca M Herrera; M Louise Cuzner
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

Review 9.  The Urokinase Plasminogen Activation System in Pancreatic Cancer: Prospective Diagnostic and Therapeutic Targets.

Authors:  Ashna A Kumar; Benjamin J Buckley; Marie Ranson
Journal:  Biomolecules       Date:  2022-01-18

Review 10.  Assessing Plasmin Generation in Health and Disease.

Authors:  Adam Miszta; Dana Huskens; Demy Donkervoort; Molly J M Roberts; Alisa S Wolberg; Bas de Laat
Journal:  Int J Mol Sci       Date:  2021-03-09       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.